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Abstract 
Necroptosis or programmed necrosis is a specialized and regulated necrosis, and is unmasked when apoptotic 
machinery for death stress is defective. Initially, it was proposed that necroptotic cell death was pathologically 
associated with ischemic brain injury and retinal disorders. In contrast, it plays a beneficial significance in 
innate immune response to viral infection that can evade host’s apoptotic surveillance. Also, it has been 
therapeutically emerging as the strategy to overcome the cancers with acquired anticancer drug resistance. 
Presently, a few small molecules to interfere with signaling pathways for necroptosis have been disclosed since 
necrostatin-1 (Nec-1) was for the first time identified as an inhibitor of receptor interacting protein 1 (RIP1), a 
key necroptosis regulator. In an effort to discover hits that can selectively inhibit necroptotic cell death, in this 
study, we screened in-house and in silico chemical libraries in a cell-based format. Eventually, 7 hits were 
identified from in-house chemical library while 2 hits were from computer modeling. Most hits less protected 
cells from tumor necrosis factor alpha (TNFα)- and zVAD-mediated necroptosis than a reference compound 
necrostatin-1, without affecting apoptotic cell death induced in HeLa. Interestingly, a few of hits had 
preferential protective effects on zVAD or TNFα while Nec-1 exhibited EC50 values at the similar 
concentrations against both necroptosis inducers, suggesting that chemicals deduced in our study can 
discriminate signaling pathways leading to receptor or nonreceptor-mediated necroptotic cell death. Therefore, 
some potent hits will be further improved to use for the treatment of necroptosis-associated disorders.    
Keywords: Necroptosis; Screening; Cell-based assa; Hit; Apoptosis. 
------------------------------------------------------------------------ 
* Corresponding author.   
International Journal of Sciences: Basic and Applied Research (IJSBAR) (2020) Volume 53, No  1, pp 152-163 
 
153 
 
1. Introduction 
Necroptosis is an emerging mode of cell demise that has been gaining great attention over the last few years, 
and it is also referred to as programmed necrosis or regulated nonapoptotic cell death [1]. Its concept was 
initially suggested as the cell death can be induced by a ligand such as TNFα (tumor necrosis factor alpha) that 
is bound to a cognate receptor like TNFα receptor (TNFR), and is later strongly supported by other signaling 
necroptosis-associated proteins and their specific inhibitors [2]. Generally, necroptosis is unmasked only under 
the specific condition that apoptotic machinery is defective in response to death stress [2]. It implies that cell 
death modalities between autophagy, apoptosis and necroptosis crosstalk each other for decision of cell fate. In 
fact, it has been suggested that a combined condition of TNFα stimulation with caspase inactivation can drive 
necroptosis through the formation of RIP1-RIP3 complex, an early key event following TNFR ligation [3-5]. 
Thereafter, it has been further discovered that mixed lineage kinase domain like protein (MLKL) and 
mitochondrial protein phosphatase (PGAM5) are crucial to execute necroptosis [6]. The formation of RIP1/RIP3 
necrosome complex dephosphorylates and then inactivates mitochondrial fission factor Drp1, which in turn 
causes mitochondrial fragmentation at an early stage of necroptosis. As a result, PGAM5 links an extracellular 
death signal to mitochondrial process, leading to necroptosis. Since the molecular understanding of necroptotic 
cell death, the discovery and optimization of small molecules with potently inhibitory activity against it have 
been explored for therapeutic uses. The first successful outcome is a series of hydantoin containing indole 
derivatives, referred to as potent necrostatins [7]. Out of hydantoin scaffold-bearing compounds, a chemical 
necrostatin-1 (Nec-1) exhibits so modest pharmacokinetic profiles as to be delivered to CNS following 
intravenous administration [8]. RIP1 was later found to be a targeting molecule of Nec-1 through in vitro kinase 
assay [9]. Since then, discovery of tricyclic derivatives [10] and substituted 3H-thienol[2,3-d]pyrimidin-4-ones 
[11] has been followed. More recently, a hit has been identified through screening a chemical library of 200,000, 
exhibiting a protective activity against necroptosis. A selected hit compound (E)-N-(4-(N-(3-methoxypyrazin-2-
yl)sulfamoyl)phenyl)-3-(5-nitrothiophene-2-yl)acrylamide is referred to as necrosulfonamide (NSA) and is 
reported to be more potent than Nec-1, with an EC50 of less than 1 M under the necrosis-inducing context. 
Finally, mixed lineage kinase domain-like (MLKL) protein was finally revealed to be a specific target of NSA, 
which can modify covalently Cys 86 residue within N-terminal CC domain of MLKL [12]. Physiologically, 
necroptosis contributes to various pathophysiological phenotypes, including ischemic brain injury, 
neurodegenerative disease, acute pancreatitis [8, 13, 14]. Also, retinal detachment-induced photoreceptor cell 
death is found to be associated with activation of RIP kinases, key proteins of necroptosis, when caspases are 
compromised [15]. Moreover, necroptosis has been reported to occur in the terminal ileum of patients with 
Crohn’s disease, suggesting a critical role of necroptotic cell death in the pathogenesis of this inflammatory 
disease [16]. With growing knowledge of necroptosis-associated diseases, needs for therapeutic drugs are being 
pursued to protect or improve the progression of necroptosis. As a part of such efforts, there has been a growing 
body of researches that the inhibition of RIP1 by Nec-1 exerts cytoprotective effects against neurodegeneration, 
adult brain ischemia, myocardial infarction and photoreceptor loss-associated retinal disorders [15, 17, 18]. 
Contrariwise, necroptosis inducers can be applicable for overcoming cancers resistant to drugs based on the 
apoptosis [19, 20]. In fact, targeting weak point of cancers resistant to apoptosis by promoting susceptibility of 
necroptosis is attracting as the significant approach of chemotherapy [21]. In pursuit of exploring hits that would 
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rescue cells from necroptotic stimuli, we set out to screen in-house chemical library (6800 chemicals) and 
computer modeling-predicted compounds in a necroptosis-prone cell line L929. Either TNFα or zVAD 
promoted necroptosis via receptor or non-receptor, respectively as reported previously [22]. This study was 
aimed at new chemical entities that could suppress necroptotic cell death via nonreceptor. To this end, we set 
out cell based assay format that can differentiate necroptotic cell death via nonreceptor or receptor. In our 
previous article, intriguingly, it was shown that RIP3 or RIP1 is required for TNFα- or zVAD-mediated 
necroptosis[22]. Some possible candidates selected through primary screening were further examined if those 
chemicals might protect cells from undergoing apoptosis. Finally, 8 hit compounds were primarily suggested to 
protect necroptosis but not apoptosis although EC50s of some were largely 10 times higher than a RIP1 inhibitor 
Nec-1. It is of note that some hits had differential effects on nonreceptor (zVAD)- and receptor (TNFα)-
mediated necroptosis. Taken together, we present structures of 9 hits that can potently and specifically inhibit 
necroptosis. To outline structural moieties responsible for anti-necroptotic activity, study on hits optimization 
will be further undertaken. 
2. Materials and Methods 
2.1. Cell lines and culture 
NIH3T3, HeLa and L929 cells were obtained from American Type Culture Collection, ATCC (Manassas, VA). 
Cell lines were grown in high glucose-Dulbecco's modified Eagle’s medium (DME) media supplemented with 
1% penicillin/streptomycin and 10% FBS, and allowed to incubate at 37°C in a 5% CO2 incubator. Cells were 
maintained under an optimal condition by dissociation and subculture of cells at low density. 
2.2. Reagents 
Tumor necrosis factor alpha (TNFα) was obtained from eBioscience (San Diego, CA, USA). RIP1 and RIP3 
antibodies were from BD Pharminigen (San Diego, CA, USA) and Prosci (Poway, CA, USA), respectively. 
MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) cell 
proliferation assay kit was bought from Promega (Madison, WI, USA). Cycloheximide (CHX), zVAD and 
necrostatin-1(Nec-1) were purchased from Sigma (St. Louis, MO, USA). Chemical resources were a 
representative chemical library from chemical bank (Korea Research Institute of Chemical Technology, 
Daejeon, South Korea), and compounds with anti-necroptosis activity were screened through an in vitro cell 
based assay and computer modeling. Other chemicals were of analytical grade. 
2.3. Induction and protection of cell death 
L929, HeLa and NIH3T3 cell lines were induced to apoptosis or necroptosis under specific death conditions. In 
brief, L929 cells were stimulated with mouse TNFα (10 ng/ml) or zVAD (10 M) to die in a necroptotic way for 
24 h. HeLa cells were grown in a combined condition of 1 g/ml cycloheximide (CHX) with 10 ng/ml human 
TNFα in the absence or presence of zVAD (10 M). Additionally, NIH3T3 was exposed to 10 ng/ml mouse 
TNFα and 1g/ml CHX along with or without 10 M zVAD. To discriminate between apoptotic and 
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necroptotic cell death, a RIP1 specific inhibitor Nec-1 was used. Cell death was evaluated by measuring cell 
viability of treated group relative to non-treated control. Cell viability was determined by MTS according to a 
protocol as described before [23]. 
2.4. Immunoblotting 
Cells harvested from L929, HeLa and NIH3T3 were disrupted in a lysis buffer and the resulting cytosolic 
proteins were subjected to sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). Proteins 
resolved on gel were transferred to nitrocellulose (NC) membranes, which were further processed to do 
immunoblot with RIP1 or RIP3 antibody. To verify equal loading, actin was probed with antibody as a reference 
protein.   
2.5. Cell-based assay for screening of antinecroptotic hits  
To identify hits with antinecroptotic potency, cell based assay using L929 cells, which are prone to undergo 
necroptotic cell death upon TNFα stimulation, was primarily employed. Compounds with protective activity of 
greater than 50% in the assay were primarily chosen as hit candidates unless otherwise stated. For the 2
nd
 round 
screening, EC50s of some selected small molecules were further calculated from dose-response curves against 
zVAD or TNFα. To check the specificity of chemicals against cell death types such as apoptosis and 
necroptosis, moreover, we examined if they could affect the apoptotic cell death induced in HeLa stimulated 
with TNFα.  
2.6. Computer modeling 
To select the compounds our in-house library, we carried out the similarity analysis based on the molecular 
properties of Nec-1. An analysis of the physicochemical properties of Nec-1 resulted in the following filter 
criteria: molecular weight < 400, H-bond donors < 2, H-bond acceptors < 5, 2<Alog P < 4, number of rings 
including aromatic rings <3, and fingerprint (FCFC4)-based similarity (DiscoveryStudio4.5) > 0.60. These 
filters helped to reduce by 235 compounds from an in-house chemical library, including 8,000 compound 
species.  
3. Results 
3.1. A schematic chart for exploring hits that could protect cells from undergoing programmed necrosis  
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Figure 1: A schematic flow chart for isolation of hits with antinecroptotic activity selectively.To find hits that 
can specifically protect cells from necroptotic stress, L929 cells, which were pretreated with various compounds 
out of a chemical library for 1 h, were stimulated with TNFα to induce necroptotic cell death. Compounds with 
protective activity of more than 50% were further subjected to 2
nd
 round screening that could test if compounds 
would be potent against either receptor (TNFα receptor)- or nonreceptor (zVAD)-mediated necroptosis in L929 
cells. Moreover, some selected compounds were examined if those compounds could prevent TNFα-mediated 
apoptosis in HeLa cell line. Finally, through this schematic procedure, chemical profiles were determined with 
respect to protective potency against programmed cell death, necroptosis and apoptosis. Test chemicals were 
available from a chemical library classified by structural diversity and novelty, and computational modeling. 
Protective potency of chemicals was primarily tested in a cell based assay, in which L929 cell line is prone to 
necroptosis upon TNFα stimulation. Compounds that could exhibit potent protective activity against necroptosis 
were subjected to the 2
nd
 round of screening. At this step, necroptosis was mediated according to receptor or 
nonreceptor death context, named TNFα or zVAD. Potent hits with EC50 around M concentration were further 
investigated if those would negatively or positively affect apoptotic cell death in HeLa cells. Finally, plausible 
necroptosis specific inhibitors were successfully deduced and then their structures were then identified from 
chemical database. 
3.2. Cellular and molecular foundations of cell based assay systems suitable for execution of apoptosis or 
necroptosis  
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Figure 2: Cell-based assays suitable for apoptosis and programmed necrosis (necroptosis). Induction and 
protection of cell death were tested in 3 different cell lines including L929, HeLa and NIH3T3 under the various 
conditions of cell death stimuli (A). Specific conditions used in this experiments were described in detail in 
Materials and Methods. L929 cells were treated with TNFα in the presence or absence of zVAD. Also, Cells 
were subjected to TNFα stimulation in combination with Nec-1. For the induction of cell death in HeLa, both 
CHX and TNFα were used. Under the condition of inducing cell death, HeLa cells were preincubated with 
either zVAD or Nec-1 to see whether cell death could be affected by those inhibitors. Finally, combined 
treatment of CHX with TNFα was required to activate cell death in NIH3T3. As with HeLa, cells were treated 
with either zVAD or Nec-1 under the cell death context of TNFα/CHX. Expression levels of RIP1 and RIP3, 
key necroptotic regulators, were investigated in L929, HeLa and NIH3T3 (B). Cell lysates (10 μg) extracted 
from each cell were run on SDS-PAGE and then transferred to nitrocellulose (NC) membrane. Transferred 
proteins were probed with antibody against RIP1or RIP3 and then visualized by chemiluminescence. For 
verification of equal loading, expression levels of actin were compared between samples. Cell death induced by 
death conditions was summarized in 3 different cells depending on caspase activity and expression level of RIP3 
on the right side of immunoblot result.      Some representative cell lines were investigated in responses to an 
inflammatory cytokine TNFα, and their cytotoxic responses to it were evaluated by MTS cell proliferation assay 
(Fig. 2A). Remarkably, L929 exerted cytotoxic responses to zVAD or TNFα, that is, necroptosis but not 
apoptosis. Either TNFα or zVAD killed cells very extensively, and their cytotoxic effects were also neutralized 
by Nec-1. In contrast, HeLa cells exhibited an apoptotic response to TNFα, and were significantly protected 
from TNFα-driven apoptosis by zVAD. However, Nec-1 did not affect TNFα-induced cell death, indicating that 
TNFα induces apoptotic cell death. NIH3T3 cells have differential cell death types depending on the death 
contexts. Particularly, apoptosis was induced when stimulated with TNFα in the presence of CHX. Intriguingly, 
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treatment of zVAD, a pan-caspase inhibitor, along with TNFα and CHX caused cells to commit an alternative 
cell type, necroptosis. As expected, however, TNFα-induced necroptotic cell death was successfully rescued by 
Nec-1, a specific RIP1 inhibitor. To seek out molecular correlation of necroptotic proteins to cell death modes, 
expression levels of two key necroptosis regulators RIP1 and RIP3 were primarily compared among cell lines 
(Fig. 2B). Both L929 and NIH3T3 expressed highly both two RIP proteins while HeLa cells did RIP1 with little 
RIP3 levels. It has been well known that caspase activity is not activated in response to TNFα stimulation. 
Therefore, L929 cells were driven to necroptosis when stimulated with TNFα due to inert caspase whereas HeLa 
cells with low expression of RIP3 committed to apoptotic cell death, but not necroptosis. Unlike L929 and HeLa 
cells, NIH3T3 cells were induced to default cell death apoptosis upon TNFα stimulation, but were diverted from 
apoptosis to necroptosis in the presence of zVAD. 
3.3. Screening hits from chemical library or modeling-designed candidates  
 
Figure 3: Summary of screening outcomes for discovery of hits with antinecroptotic potency. The dotted line 
represents protection cutoff (50%) drawn for the primary screen of hit candidates. Compounds suggested from a 
chemical library or computer modeling were assayed for protective activity against TNFα-mediated necroptosis 
in L929 cells. Each compound from chemical sources was sorted in the decreasing order of protective potency 
(A). Probability of selecting compounds with protective activity of more than 50% are approximately 0.12% and 
1.28%, respectively, from a chemical library and computer modeling-deduced chemicals. When compounds 
were sorted by protective percentage (B), a few of compounds effectively protected cells from TNFα-mediated 
necroptosis, representing that only 15 and 2 compounds, respectively, exerted protective activity of more than 
50% out of chemicals from different sources. 
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We carried out the cell-based assay using L929 cell line/TNFα stimulation in order to choose small molecules 
that can effectively protect cells from TNFα stimulation. Protective potencies of 6500 and 235 compounds, 
suggested from chemical library and computer modeling, were expressed as percent protection of each chemical 
against TNFα toxicity relative to a non-stimulated group (Fig. 3A). Compounds at a fixed concentration of 1 M 
were sorted in a decreasing order as to how much those compounds could rescue L929 cells from TNFα 
exposure. Those protective potencies were widely ranged from about 70% to nothing. When plotting the graph 
by chemical numbers per % protective activity, hits with protective activity of greater than 50 % accounted for 
at most 0.1% and 1% out of a chemical library and modeling compounds, respectively (Fig. 3B). 
3.4. Molecular docking  
We carried out docking experiment using 4ITH (pdb code) structure, showing Nec-1 derivative’s binding mode 
against RIP1K [24]. LigandFit method in DiscoveryStudio4.5 program was used for docking. As shown in Fig 
4, compound 9 well docked having H-bond with D156 residue.  
 
Figure 4: The binding mode of compound 9 against RIP1. The green lines represents H-bond. 
3.5. Structure of hits, and their comparative antinecroptotic activities (Table 1) 
Finally, disclosed were structures of 9 compounds over 50% cut-off level through the primary screening. The 
selected compounds with protective activities against necroptosis were investigated for receptor- or nonreceptor-
mediated necroptosis with preferential selectivity for necroptosis over apoptosis (Table 1). Dose-response 
curves of selected compounds revealed that their EC50 values against TNFα were largely calculated to 2- 10 M, 
a little higher than those of Nec-1. In response to zVAD stimulation, compound 1, 2, 4 and 6 did not show 
protective effects at the highest concentration used (20 M), but the rests were potent, presenting EC50 values of 
0.1-3 M. In contrast, all the hits did not affect apoptotic cell death of HeLa treated with TNFα at the 
concentrations used. Intriguingly, compound 9 which showed high similarity score (FCFC4 > 0.7) is 
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comparable or superior to Nec-1 with respect to the protective potency against zVAD-mediated necroptosis.  
Table 1: Antinecroptotic activities of hits selected from screening of in-house chemical library and computer 
modeling-deduced chemicals. In-house chemical library was from KRICT, including about 6800 chemicals 
classified by representative chemical moiety. Also, some chemicals were suggested from database of chembank 
(KRICT) through computer modeling. Nine compounds selected from primary screening were further assayed to 
plot dose-response curves against TNFα- or zVAD-driven necroptosis, and then EC50 of each compound was 
calculated using GraphPad Prism software. 
 
* and ** represent no significant protection at a concentration of 50 μM in the following cell based assays of 
zVAD-mediated necroptosis in L929 and TNFα-induced apoptosis in HeLa, respectively. 
4. Discussion 
Since physiological significances of necroptosis were emphasized, a few molecular targets for necroptosis and 
specific inhibitors have been extensively explored. As a result, a cascade of signaling pathway and underlying 
molecular mechanism leading to necroptosis has been in part established. Particularly, some antinecroptotic 
chemical probes can be useful for not only drug development for treatment of neurodegenerative diseases, but 
also identification and validation of target molecules associated with necroptosis. In fact, discovery of Nec-1 
and necrosulfonamide (NSA) makes it possible to identify a corresponding specific molecular target in L929 
cells stimulated with TNFα [9, 12]. To this end, a suitable assay system whatever it may be based on target 
molecules or phenotypes is prerequisite. To date, a cell based format is conveniently used for primary screening 
of chemicals due to incompatibility of enzymatic activity of necroptosis-related proteins to high throughput 
screening (HTS). In an attempt to improve a cell based assay for screening chemicals against necroptosis, 3 
different cell lines were examined. Out of cell lines derived from normal or cancer tissues, only NIH3T3 
committed the fate of both apoptosis and necroptosis when stimulated with TNFα in the absence or presence of 
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zVAD. Consistent with a previous article, in our results, L929 cells exhibited an atypical response to TNFα, 
mediating necroptosis rather than a default programmed cell death apoptosis when stimulated with it [25]. Later, 
our study suggests that zVAD and TNFα caused necroptosis in a RIP1- and a RIP3-dependent pathway, 
respectively. It can be explained by unmasking of necroptosis resulting from defects in the activation of 
caspases upon TNF stimulation [22]. In HeLa cell line, TNFα induced so extensively apoptosis that its cell death 
could completely reversed by zVAD, a caspase inhibitor. RIP1 and RIP3 are proximal necroptosis regulators 
following TNFR ligation, and their complex formation between RIPs is required for driving necroptosis. 
Interestingly, there was generally high expression of RIP1 in 3 cell lines under investigation, but notably little 
expression of RIP3 in HeLa. Therefore, TNFα-stimulated HeLa cells could not transduce death signals to 
necroptotic cell death due to RIP3 insufficiency and then failure in complex formation of RIP1/RIP3. Based on 
molecular foundations associated with cell death, flow chart can be made for subsequent procedures to discover 
hits with antinecroptotic activity. That is, inhibitors with protective potency more than 50% were primarily 
selected out of chemical compounds in TNFα-driven necroptotic prone cell line L929. EC50s of selected 
compounds were calculated from dose-response curves against zVAD or TNFα, respectively. Some potent 
chemicals were further examined for anti-apoptotic activity in HeLa cells, apoptosis-prone cells. Through these 
screening processes, 9 hits were finally deduced and then their structures were identified. Interestingly, some 
hits (2, 4 and 6) exhibited protective activity against zVAD and TNFα with EC50 around 3 μM although most 
hits are less effective than a reference compound Nec-1. Some (compound 3, 5 and 7) had preferential 
inhibitory activity against TNFα over zVAD. In contrast, EC50 values of compound 8 and 9 for zVAD had 
10~20 times lower than those for TNFα. Chemical probes with differential inhibitory profiles make it very 
useful to interfere with the signaling pathways at the specific targets. Thereafter, hits will be chemically 
modified to improve protective activity and selectivity based on the predicted binding mode.  
5. Conclusions 
Small molecules that protect cells from necroptotic cell death were screened through cell-based assay from a 
representative chemical library and computer modeling-proposed candidates. As a result, nine hits were 
demonstrated to have a protective activity against necroptosis but not apoptosis. All the hits were not 
comparable to Nec-1 with respect to protective potency against TNFα or zVAD, but some hits showed 
specifically antinecroptotic activity for zVAD over TNFα, indicating that necroptosis may be mediated via 
different routes, receptor or nonreceptor ligand. This study supported the notion that zVAD or TNFα could 
execute cell death in a RIP1- or RIP3-dependent way. Moreover, it introduced the cell based assay that could 
effectively screen potent antinecroptotic small molecules for therapeutic uses. Therefore, this study highlights 
that hits have a potency to protect effectively necroptotic stresses from zVAD and TNFα. However, deduced 
hits are so chemically different from known antinecroptosis chemicals that those compounds have structural 
versatility to get them modified. Consequently, novel molecular targets for hits will additionally be identified to 
fill in the gaps between necroptotic molecules leading to signaling pathway associated with necroptosis.  
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